SENATE FLOOR VERSION - SB131 SFLR Page 1
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SENATE FLOOR VERSION
February 8, 2021
SENATE BILL NO. 131 By: Garvin of the Senate
and
McEntire of the House
An Act relating to pharma cy; amending 59 O.S. 2011,
Section 353.18, as last amended b y Section 4, Chapter
285, O.S.L. 2016 (59 O.S. Supp. 2020, Section
353.18), which relates to the sale, manufacturing or
packaging of dangerous drugs; providing licensure
exception; providing excep tion to pharmacy
requirements for facilities distributing or
dispensing dialysate or devices necess ary for
peritoneal dialysis; amending 59 O.S. 2011, Section
353.24, as last amended by Section 6, Chapter 106,
O.S.L. 2018 (59 O.S. Supp. 20 20, Section 353.24),
which relates to unlawful acts; providing certain
construction; providing certification exception; and
providing an effective date .
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. AMENDATORY 59 O.S. 2011, Section 353.18 , as
last amended by Secti on 4, Chapter 285, O.S.L. 2016 (59 O.S. Supp.
2020, Section 353.18), is amended to read as follows:
Section 353.18. A. 1. It shall be unlawful for any person,
including, but not limited to, Internet, website or online
pharmacies, to sell at retail or to offer for sale, dangerous drugs,
medicines, chemicals or poisons for the treatment of disease,
SENATE FLOOR VERSION - SB131 SFLR Page 2
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
excluding agricultural chemicals and drugs, or to accept
prescriptions for same, without first procuring a license from the
State Board of Pharmacy. This licens ure requirement applies whether
such sale, offer for sale or acceptance of prescriptions occurs in
this state, or such sale, offer for sale, or acceptance of
prescription prescriptions occurs out of state and the dangerous
drug, medicine, chemical or poiso n is to be delivered, distributed
or dispensed to patients or customers in this state. This licensure
requirement shall not apply to the distribution or dispensing of
dialysate or peritoneal dialysis devices to patients with end -stage
renal disease (ESRD) consistent with subsection F of this section.
2. A pharmacy license shall be issued to such person as the
Board shall deem qualified upon evidence satisfactory to the Board
that:
a. the place for which the license is sought will be
conducted in full comp liance with the law and the
rules of the Board,
b. the location and physical characteristics of the place
are reasonably consistent with the maintenance of
professional surroundings and constitute no known
danger to the public hea lth and safety,
c. the place will be under the management and control of
a licensed pharmacist or pharmacist-in-charge who
shall be licensed as a pharmacist in Oklahoma, and
SENATE FLOOR VERSION - SB131 SFLR Page 3
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
d. a licensed pharmacist shall be present and on duty at
all business hours; provi ded, however, the provisio ns
of this subparagraph shall not apply to hospita l drug
rooms.
3. a. An application for an initial or renewal licens e
issued pursuant to the provisions of this subsection
shall:
(1) be submitted to the Board in writing,
(2) contain the name or names of pe rsons owning the
pharmacy, and
(3) provide other such information deemed relevant by
the Board.
b. An application for an initial or renewal license shall
be accompanied by a licensing fee not to exceed Three
Hundred Dollars ($300. 00) for each period of one (1)
year. Prior to opening for business, all app licants
for an initial license or permit shall be inspected.
An initial licensure applicant shall pay an inspection
fee not to exceed Two Hundred Dollars ($200.00);
provided, however, that no charge shall be made for
the licensing of any Federal Veterans Hospital in the
State of Oklahoma. Non -resident pharmacies shall
reimburse the Board for any actual expenses incurred
for inspections.
SENATE FLOOR VERSION - SB131 SFLR Page 4
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
c. A license issued pursuant to the provisio ns of this
subsection shall be valid for a period set by the
Board and shall contain the name of the licensee and
the address of the place at w hich such business shall
be conducted.
4. A retail pharmacy that prepares sterile drugs shall obtain a
pharmacy license, and shall also ob tain a sterile compounding permit
at a fee set by the Board, not to exceed Seventy-five Dollars
($75.00). Such pharm acy shall meet requirements set by the Board by
rule for sterile compounding permits.
5. An outsourcing facility desiring to dispense pres criptions
to patients must additionally license an d meet the requirements of a
pharmacy.
B. 1. It shall be unlawful for any person to manufacture,
repackage, distribute, outsource, warehouse or be a third -party
logistics provider of any dangerous drugs, medicines, medical gases,
chemicals, or poisons fo r the treatment of disease, excluding
agricultural chemicals , without first procuring a license from the
Board. It shall be unlawful to sell or offer for sale at retail or
wholesale dangerous drugs, medici nes, medical gases, chemicals or
poisons without first procuring a license from the Board. This
licensure requiremen t shall apply when the manufacturing,
repackaging, distributing, outsourcing, warehousing, or provision of
third-party logistics occurs in this state or out of state for
SENATE FLOOR VERSION - SB131 SFLR Page 5
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
delivery, distribution, or dispensing to patients or customers in
this state.
2. A license shall be issued to such person as the Board shall
deem qualified upon satisfactory evidence to the Board th at:
a. the place for which the license is sought will be
conducted in full compliance with the laws of this
state and the administrative rules of the Board,
b. the location and physical characteristics of the place
of business are reasonably consistent wit h the
maintenance of profe ssional surroundings and
constitute no known dange r to public health and
safety,
c. the place shall be under the mana gement and control of
such persons as may be approved by the Board after a
review and determination of the person s’
qualifications, and
d. an outsourcing facility shall designate in writing on
a Board-approved form a person to serve as the
pharmacist-in-charge who is a pharmacist licensed by
the Board.
3. a. An application for an initial or renewal license
issued pursuant to the provisions of this subsection
shall:
(1) be submitted to the Bo ard in writing,
SENATE FLOOR VERSION - SB131 SFLR Page 6
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(2) contain the name or names of the owners or the
applicants, and
(3) provide such other information deemed relevant by
the Board.
b. An application for an initial or renewal license shall
be accompanied by a licensing fee not to exceed Th ree
Hundred Dollars ($300.00) for each period of one (1)
year. Prior to opening for business, all applicants
for initial or renewal license shall be inspected. An
initial licensure applicant shall pay an inspection
fee not to exceed Two Hundred Dollars ( $200.00). Non-
resident applicants shall reimburse the Board for an y
actual expenses incurred for inspections.
c. A license issued pursuant to the provisions of this
subsection shall contain the name of the licensee and
the address of the place at which su ch business shall
be conducted and shall be valid for a period of t ime
set by the Board.
C. A licensee or permit holder who, pursuant to the provisions
of this section, fails to c omplete an application for a renewal
license or permit by the fifteenth day after the expiration of the
license or permit shall pay a late fee to be fixed by the Board.
D. 1. The Board shall promulgate rules regarding the issuance
and renewal of licenses and permits pursuant to t he Oklahoma
SENATE FLOOR VERSION - SB131 SFLR Page 7
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Pharmacy Act which shall include, but need not be limited to,
provisions for new or renewal application r equirements for its
licensees and permit holders. Requirements for new and renewal
applications may include, but need not be limited to, t he following:
a. type of ownership, whether indivi dual, partnership,
limited liability company or corporation,
b. names and addresses of principal owners or officers
and their Social Security numbers, including
applicant’s full name, all trade or business names
used, full business address, telephone numbe rs, and
email addresses,
c. names of designated representatives and facility
managers and their Social Security numbers and dates
of birth,
d. evidence of a criminal background che ck and
fingerprinting of the applicant, if a person, and all
of the applicant’s designated representatives and
facility managers,
e. a copy of the license from the applicant ’s home state,
and if applicable, from the federal government,
f. bond requirements, and
g. any other information deemed by the Board to be
necessary to protect the public health and safety.
SENATE FLOOR VERSION - SB131 SFLR Page 8
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. The Board shall be authorized t o use an outside agency, such
as the National Association of Boards of Pharmacy (NABP) or the
Verified-Accredited Wholesale Distributors (V AWD), to accredit
wholesale distributors and repac kagers.
E. The Oklahoma Pharmacy Act shall not be construed to pre vent
the sale of nonprescription drugs in original manufacturer packages
by any merchant or dealer.
F. The Oklahoma Pharmacy Act shall not be construed to apply to
a facility engaged in th e distribution or dispensing to patients of
dialysate or peritoneal dialysis devices necessary to perform home
peritoneal dialysis, provided the following criteria are met:
1. The dialysate is comprised of dextrose or icodextrin;
2. The dialysate or peri toneal dialysis devices are approved or
cleared by the United State s Food and Drug Administration;
3. The dialysate or peritoneal dialysis devices are lawfully
held by a manufacturer, or the manufacturer ’s agent, who is properly
licensed by the Board as a manufacturer, wholesaler or distributor;
4. The dialysate or peri toneal dialysis devices are held and
delivered in their original, sealed packaging from the manufacturing
facility;
5. The dialysate or pe ritoneal dialysis devices are delivered
only upon receipt of a physician’s prescription by a licensed
pharmacy, and the transmittal of an order from the licensed pharmacy
to the manufacturer or the manufacturer ’s agent; and
SENATE FLOOR VERSION - SB131 SFLR Page 9
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
6. The manufacturer or agent of the manufacturer delivers the
dialysate or peritoneal dialysis devices directly to:
a. a patient with ESRD or the patient’s designee for the
patient’s self-administration of the dialysis therapy,
or
b. a health care provider or institution for
administration or delivery of the dialysis therapy to
the patient with ESRD.
SECTION 2. AMENDATORY 59 O.S. 2011, Section 353.24, as
last amended by Section 6, Chapter 106, O.S.L. 2018 (59 O.S. Supp.
2020, Section 353.24), is amended to r ead as follows:
Section 353.24. A. It shall be unlaw ful for any licensee or
other person to:
1. Forge or increase t he quantity of drug in any prescription,
or to present a prescription bearing forged, fictitious or altered
information or to possess any d rug secured by such forged,
fictitious or altered pre scription;
2. Sell, offer for sale, barter or give away any unu sed
quantity of drugs obtained by prescription, except through a program
pursuant to the Utilization of Unused Pr escription Medications Act
or as otherwise provided by the State Board of Pharm acy;
3. Sell, offer for sale, barter or give away any drugs dam aged
by fire, water, or other causes without first obtaining the written
approval of the Board or the State Depar tment of Health;
SENATE FLOOR VERSION - SB131 SFLR Page 10
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
4. No person, firm or business establishment shall offer to t he
public, in any manner, their services as a “pick-up station” or
intermediary for the purpose of having prescriptions filled or
delivered, whether for profit or gratuitously. Nor may the owner of
any pharmacy or drug store authorize any person, firm or business
establishment to act for them in this manner with these exceptions:
a. patient-specific filled prescriptions may be delivered
or shipped to a prescriber ’s clinic for pick-up by
those patients whom the prescriber has individually
determined and documented do not have a permanent or
secure mailing address,
b. patient-specific filled prescriptions for drugs which
require special handling written by a prescriber may
be delivered or shipped to the pre scriber’s clinic for
administration or pick -up at the prescriber’s office,
c. patient-specific filled prescriptions, including
sterile compounded drugs, may be delivered or shipped
to a prescriber’s clinic where they shall be
administered,
d. patient-specific filled prescriptions for patients
with End Stage Renal Disease end-stage renal disease
(ESRD) may be delivered or shipped to a prescriber ’s
clinic for administration or final delivery to the
patient,
SENATE FLOOR VERSION - SB131 SFLR Page 11
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
e. patient-specific filled prescriptions for
radiopharmaceuticals may be del ivered or shipped to a
prescriber’s clinic for administration or pick-up, or
f. patient-specific filled prescriptions may be delivered
or shipped by an Indian Health Services (IHS) or
federally recognized tribal health organizatio n
operating under the IHS in the delivery of the
prescriptions to a pharmacy operated by the IHS or a
federally recognized tribal health organi zation for
pick-up by an IHS or tribal patient.
However, nothing in this paragraph shall prevent a pharmacist or
an employee of the pharmac y from personally receiving a prescription
or delivering a legally filled prescription to a residence, office
or place of employment of the patient for whom the prescription was
written. Provided further, the provisions of this p aragraph shall
not apply to any Department of Mental Health and Substance Abuse
Services employee or any person whose facility contracts with t he
Department of Mental Health and Substance Abuse Services whose
possession of any dangerous drug, as defined in Section 353.1 of
this title, is for the purpose of delivery of a mental health
consumer’s medicine to the consumer ’s home or residence. Nothi ng in
this paragraph shall prevent veterinary prescription drugs from
being shipped directly from an Oklahoma lic ensed wholesaler or
distributor registered with the Oklahoma Board of Veterinary Medical
SENATE FLOOR VERSION - SB131 SFLR Page 12
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Examiners to a client; provided, such drugs may be dis pensed only on
prescription of a licensed veterinarian and only when an existing
veterinary-client-patient relationship exists. Nothing in this
paragraph shall prevent dialysate and peritoneal dialysis devices
from being shipped directly from an Oklahoma licensed manufacturer,
wholesaler or distributor to an ESRD patient or patient ’s designee,
consistent with subsec tion F of Section 353.18 o f this title;
5. Sell, offer for sale or barter or buy any professional
samples except through a program pursuant to the Utilization of
Unused Prescription Medications Act;
6. Refuse to permit or otherwise prevent members of the Board
or such representatives thereof from entering and inspecting any and
all places, including premises, vehicles, equipment, contents, and
records, where drugs, medicine, chemicals or poisons are stored,
sold, vended, given away, compounded, dispensed, repackaged,
transported, or manufactured;
7. Interfere, refuse to participate in, impede or otherwise
obstruct any inspection, investigation or disciplinary proceeding
authorized by the Oklahoma Pharmacy Act;
8. Possess dangerous drugs without a valid p rescription or a
valid license to possess such drugs; provided, however, this
provision shall not apply to any Department of Mental Health and
Substance Abuse Services employee or any person whose facility
contracts with the Department of Mental Health and Substance Abuse
SENATE FLOOR VERSION - SB131 SFLR Page 13
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Services whose possession of any dangerous drug, as defined in
Section 353.1 of this title, is for the purpose of delivery of a
mental health consumer ’s medicine to the consumer ’s home or
residence;
9. Fail to establish and maintain effec tive controls against
the diversion of drugs for any other purpose than legitimate
medical, scientific or industrial uses as provided by state, federal
and local law;
10. Fail to have a written drug diversion detection and
prevention policy;
11. Possess, sell, offer for sale, bar ter or give away any
quantity of dangerous drugs not listed as a scheduled drug pursuant
to Sections 2-201 through 2-212 of Title 63 of the Oklahoma Statutes
when obtained by prescription bearing forged, fictitious or altered
information.
a. A first violation of this section shall constitute a
misdemeanor and upon conviction shall be punishable by
imprisonment in the cou nty jail for a term not more
than one (1) year and a fine in an amount not more
than One Thousand Dollars ($1,000 .00).
b. A second violation of this section shall constitute a
felony and upon conviction shall be punishable by
imprisonment in the Department of Corrections for a
SENATE FLOOR VERSION - SB131 SFLR Page 14
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
term not exceeding five (5) years and a fine in an
amount not more than Two Thousand Dollar s ($2,000.00);
12. Violate a Board order or agreed order;
13. Compromise the security of licensure examination materials;
or
14. Fail to notify the Board, in writing, within ten (10) days
of a licensee or permit holder ’s address change.
B. 1. It shall be unlawful for any perso n other than a
licensed pharmacist or physician to certify a prescription before
delivery to the patient or the patie nt’s representative or
caregiver. Dialysate and peritoneal dialysis devices supplied
pursuant to the provisions of subsection F of Section 353.18 of this
title shall not be required to be certified by a pharmacist prior to
being supplied by a manufacturer , wholesaler or distributor.
2. It shall be unlawful for any person to institute or manage a
pharmacy unless such person is a licensed pha rmacist or has placed a
licensed pharmacist in charge of such pharmacy.
3. No licensed pharmacist shall manage, supe rvise or be in
charge of more than one pharmacy.
4. No pharmacist being requested to sell, furnish or compound
any drug, medicine, chemica l or other pharmaceutical preparation, by
prescription or otherwise, shall substitute or cause to be
substituted for it, without authority of the prescriber or
SENATE FLOOR VERSION - SB131 SFLR Page 15
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
purchaser, any like drug, medicine, chemical or pharmaceutical
preparation.
5. No pharmacy, pha rmacist-in-charge or other person shall
permit the practice of pharmacy except by a licensed pharmacist or
assistant pharmacist.
6. No person shall subvert the authority of the pharmacist -in-
charge of the pharmacy by impeding the management of the
prescription department to act in compliance with federal and state
law.
C. 1. It shall be unlawful for a pharmacy to rese ll dangerous
drugs to any wholesale distributor.
2. It shall be unlawful for a wholesale distributor to purchase
drugs from a pharmacy.
SECTION 3. This act shall become effective November 1, 202 1.
COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
February 8, 2021 - DO PASS